睾丸生殖细胞瘤（TGCT）是年轻男性最常见的诊断癌症。尽管这些肿瘤通常预后良好且易治疗，但临床医生和病理学家仍面临与这种肿瘤模型固有的特定困境，这在很大程度上是由于其发育起源而引起的。本文介绍了关于TGCT生物标志物目前可用和未来前景的广泛评论。 TGCT生物标志物的领域在过去十年中得到了广泛研究。尽管这些患者通常预后良好，但仍需要新型生物标志物来补充临床中已经使用的标志物。这些问题包括临床一期患者的随访方法，最小残留病的检测，瘤性胚细胞的正确鉴定以及根据其固有抗性选择化疗患者的合适选择。

Testicular germ cell tumors (TGCT) are the most commonly diagnosed cancers amongst young men. Although these tumors usually have a good prognosis and are highly treatable, clinicians and pathologists still face specific dilemmas inherent to this tumor model, which is highly due to its developmental origin.A wide-ranging review of the currently available and future prospects in the field of TGCT biomarkers is presented.TGCT biomarkers' field has been widely studied in the last decade. Although these patients usually present with good prognosis, there are still specific clinical questions where novel biomarkers are needed to complement the ones already used in the clinic. These questions include the follow-up method of clinical stage-I patients, detection of minimal residual disease, proper identification of teratoma and suitable selection of patients to chemotherapy, according to their inherent resistance.